List of investigational aggression drugs

Phase 3 • Molindone (AFX 2201; EN-1733A; -810; SPN-810M; Zalvari) – antipsychotic (non-selective monoamine receptor modulator) – specifically for aggression in children and adolescents with attention-deficit hyperactivity disorder (ADHD) Phase 2 • KNX-100 (SOC-1) – oxytocin-like drug / indirect oxytocin receptor modulator [https://synapse.patsnap.com/drug/42d34da2e8a3426084cdfc75bfeaf334 • Vafidemstat (ORY-2001) – lysine-specific demethylase 1 (LSD1; KDM1A) and monoamine oxidase B (MAO-B) inhibitor Preclinical • SRX251 – vasopressin V1A receptor antagonist – no recent development since 2007 ==Not under development==

No development reported • Eltoprazine (DU-28853) – serotonin 5-HT1A and 5-HT1B receptor agonist and serotonin 5-HT2C receptor antagonist Development discontinued • Batoprazine – serotonin 5-HT1A and 5-HT1B receptor agonist • Mibampator (LY-451395) – ionotropic glutamate AMPA receptor positive allosteric modulator • Olanzapine intranasal (INP-105; POD olanzapine) – atypical antipsychotic (non-selective monoamine receptor modulator) • Risperidone extended-release (Risperisphere) – atypical antipsychotic (non-selective monoamine receptor modulator) Formal development never or not yet started • Antiandrogens (e.g., cyproterone acetate, medroxyprogesterone acetate, GnRH modulators) • Other serotonin 5-HT1A and 5-HT1B receptor agonists (e.g., fluprazine) • Selective 5-HT1B receptor agonists (e.g., anpirtoline, CP-94253) • Serotonin 5-HT1B and 5-HT1D receptor agonists (e.g., PGI-7043) • Serotonin 5-HT2C receptor agonists (e.g., lorcaserin) • Serotonin releasing agents (e.g., fenfluramine) • Trace amine-associated receptor 1 (TAAR1) agonists (e.g., RO5263397) ==Clinically used drugs==

Approved drugs • Olanzapine (Zyprexa) – atypical antipsychotic (non-selective monoamine receptor modulator) • Paliperidone (Invega) – atypical antipsychotic (non-selective monoamine receptor modulator) • Risperidone (Risperdal) – atypical antipsychotic (non-selective monoamine receptor modulator) Off-label drugs • α2-Adrenergic receptor agonists (e.g., clonidine, dexmedetomidine, guanfacine) • Anticonvulsants (e.g., valproic acid, divalproex, carbamazepine, oxcarbazepine, phenytoin, lamotrigine, topiramate, gabapentin, tiagabine) • Antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs) like sertraline) (but may exacerbate aggression) • Benzodiazepines (e.g., diazepam, lorazepam, midazolam) • Beta blockers (β-adrenergic receptor antagonists) (e.g., propranolol, pindolol, nadolol) • Lithium – mood stabilizer with unknown mechanism of action • Norepinephrine reuptake inhibitors (NRIs) (e.g., atomoxetine) (but may exacerbate aggression) ==See also==